Integration of capecitabine (X) into adjuvant therapy comprising docetaxel (T) followed by 5-FU, epirubicin, and cyclophosphamide (CEF): Efficacy in patients with triple-negative breast cancer (BC).
Heikki Joensuu(Orion Corporation (Finland)), Henrik Lindman(Uppsala University), Päivi Auvinen(University of Eastern Finland), James D. Ahlgren(Helsinki University Hospital), Peter Bono(Dana-Farber Cancer Institute), Riikka Huovinen(Turku University Hospital), Pirkko Kellokumpu‐Lehtinen(Tampere University Hospital), R. Kokko, M. Tanner, Arja Jukkola‐Vuorinen(University of Oulu)
Cited by 6
Related Papers
Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors
|New England Journal of Medicine|2002|4.4k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
|New England Journal of Medicine|2006|1.4k